Cargando…
Use of PCSK9 Inhibitors in Solid Organ Transplantation Recipients
Standard lipid-lowering therapies in solid organ transplantations pose challenges due to interactions with immunosuppressants. Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) represent a new class of lipid-lowering therapies with potential promise in this population. We describe PC...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311616/ https://www.ncbi.nlm.nih.gov/pubmed/34317250 http://dx.doi.org/10.1016/j.jaccas.2019.09.026 |
_version_ | 1783728994672181248 |
---|---|
author | Warden, Bruce A. Kaufman, Tina Minnier, Jessica Duell, P. Barton Fazio, Sergio Shapiro, Michael D. |
author_facet | Warden, Bruce A. Kaufman, Tina Minnier, Jessica Duell, P. Barton Fazio, Sergio Shapiro, Michael D. |
author_sort | Warden, Bruce A. |
collection | PubMed |
description | Standard lipid-lowering therapies in solid organ transplantations pose challenges due to interactions with immunosuppressants. Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) represent a new class of lipid-lowering therapies with potential promise in this population. We describe PCSK9i as an efficacious and safe option for management of hypercholesterolemia in solid organ transplantations. (Level of Difficulty: Advanced.) |
format | Online Article Text |
id | pubmed-8311616 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-83116162021-07-26 Use of PCSK9 Inhibitors in Solid Organ Transplantation Recipients Warden, Bruce A. Kaufman, Tina Minnier, Jessica Duell, P. Barton Fazio, Sergio Shapiro, Michael D. JACC Case Rep Mini-Focus Issue on Heart Failure Standard lipid-lowering therapies in solid organ transplantations pose challenges due to interactions with immunosuppressants. Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) represent a new class of lipid-lowering therapies with potential promise in this population. We describe PCSK9i as an efficacious and safe option for management of hypercholesterolemia in solid organ transplantations. (Level of Difficulty: Advanced.) Elsevier 2020-02-12 /pmc/articles/PMC8311616/ /pubmed/34317250 http://dx.doi.org/10.1016/j.jaccas.2019.09.026 Text en © 2020 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Mini-Focus Issue on Heart Failure Warden, Bruce A. Kaufman, Tina Minnier, Jessica Duell, P. Barton Fazio, Sergio Shapiro, Michael D. Use of PCSK9 Inhibitors in Solid Organ Transplantation Recipients |
title | Use of PCSK9 Inhibitors in Solid Organ Transplantation Recipients |
title_full | Use of PCSK9 Inhibitors in Solid Organ Transplantation Recipients |
title_fullStr | Use of PCSK9 Inhibitors in Solid Organ Transplantation Recipients |
title_full_unstemmed | Use of PCSK9 Inhibitors in Solid Organ Transplantation Recipients |
title_short | Use of PCSK9 Inhibitors in Solid Organ Transplantation Recipients |
title_sort | use of pcsk9 inhibitors in solid organ transplantation recipients |
topic | Mini-Focus Issue on Heart Failure |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311616/ https://www.ncbi.nlm.nih.gov/pubmed/34317250 http://dx.doi.org/10.1016/j.jaccas.2019.09.026 |
work_keys_str_mv | AT wardenbrucea useofpcsk9inhibitorsinsolidorgantransplantationrecipients AT kaufmantina useofpcsk9inhibitorsinsolidorgantransplantationrecipients AT minnierjessica useofpcsk9inhibitorsinsolidorgantransplantationrecipients AT duellpbarton useofpcsk9inhibitorsinsolidorgantransplantationrecipients AT faziosergio useofpcsk9inhibitorsinsolidorgantransplantationrecipients AT shapiromichaeld useofpcsk9inhibitorsinsolidorgantransplantationrecipients |